JP2017532014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532014A5 JP2017532014A5 JP2017511696A JP2017511696A JP2017532014A5 JP 2017532014 A5 JP2017532014 A5 JP 2017532014A5 JP 2017511696 A JP2017511696 A JP 2017511696A JP 2017511696 A JP2017511696 A JP 2017511696A JP 2017532014 A5 JP2017532014 A5 JP 2017532014A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- domain
- receptor
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 24
- 231100000433 cytotoxic Toxicity 0.000 claims 21
- 230000001472 cytotoxic effect Effects 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 239000013598 vector Substances 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 238000004458 analytical method Methods 0.000 claims 11
- 230000004962 physiological condition Effects 0.000 claims 11
- 230000002159 abnormal effect Effects 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 230000027455 binding Effects 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- -1 CD86 Proteins 0.000 claims 7
- 238000002703 mutagenesis Methods 0.000 claims 7
- 231100000350 mutagenesis Toxicity 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 3
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 3
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 241000714192 Human spumaretrovirus Species 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000003651 basophil Anatomy 0.000 claims 2
- 238000009109 curative therapy Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 1
- 108010008629 CA-125 Antigen Proteins 0.000 claims 1
- 102000007269 CA-125 Antigen Human genes 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 101150064015 FAS gene Proteins 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 102000010451 Folate receptor alpha Human genes 0.000 claims 1
- 108050001931 Folate receptor alpha Proteins 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 1
- 108010073816 IgE Receptors Proteins 0.000 claims 1
- 102000009438 IgE Receptors Human genes 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102100022337 Integrin alpha-V Human genes 0.000 claims 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims 1
- 102100025390 Integrin beta-2 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 101150028321 Lck gene Proteins 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010063954 Mucins Proteins 0.000 claims 1
- 102000015728 Mucins Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 1
- 108700012411 TNFSF10 Proteins 0.000 claims 1
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 108010065472 Vimentin Proteins 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 229950001537 amatuximab Drugs 0.000 claims 1
- 238000007845 assembly PCR Methods 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000012219 cassette mutagenesis Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 108091007930 cytoplasmic receptors Proteins 0.000 claims 1
- 210000005220 cytoplasmic tail Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 229950010640 ensituximab Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 238000007834 ligase chain reaction Methods 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 238000002515 oligonucleotide synthesis Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 208000018964 sebaceous gland cancer Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000008759 sweat gland cancer Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000005048 vimentin Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021082062A JP7405444B2 (ja) | 2014-08-28 | 2021-05-14 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043067P | 2014-08-28 | 2014-08-28 | |
| US62/043,067 | 2014-08-28 | ||
| PCT/US2015/047197 WO2016033331A1 (en) | 2014-08-28 | 2015-08-27 | Conditionally active chimeric antigen receptors for modified t-cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021082062A Division JP7405444B2 (ja) | 2014-08-28 | 2021-05-14 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532014A JP2017532014A (ja) | 2017-11-02 |
| JP2017532014A5 true JP2017532014A5 (https=) | 2018-09-20 |
| JP7286267B2 JP7286267B2 (ja) | 2023-06-05 |
Family
ID=55400578
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511696A Active JP7286267B2 (ja) | 2014-08-28 | 2015-08-27 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
| JP2018530483A Active JP7048494B2 (ja) | 2014-08-28 | 2016-02-24 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
| JP2021082062A Active JP7405444B2 (ja) | 2014-08-28 | 2021-05-14 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530483A Active JP7048494B2 (ja) | 2014-08-28 | 2016-02-24 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
| JP2021082062A Active JP7405444B2 (ja) | 2014-08-28 | 2021-05-14 | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20170260261A1 (https=) |
| EP (3) | EP3186284B1 (https=) |
| JP (3) | JP7286267B2 (https=) |
| KR (4) | KR102818922B1 (https=) |
| CN (2) | CN107074975A (https=) |
| AU (3) | AU2015308818B2 (https=) |
| BR (1) | BR112018003535A2 (https=) |
| CA (1) | CA2996514A1 (https=) |
| DK (2) | DK4074735T3 (https=) |
| ES (2) | ES2913865T3 (https=) |
| HK (1) | HK1246803A1 (https=) |
| MX (4) | MX2017002605A (https=) |
| RU (2) | RU2764074C2 (https=) |
| WO (2) | WO2016033331A1 (https=) |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| US11111288B2 (en) * | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016033331A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| US10434153B1 (en) | 2015-05-20 | 2019-10-08 | Kim Leslie O'Neill | Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| RU2766690C2 (ru) | 2015-07-28 | 2022-03-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения |
| US11352439B2 (en) * | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| WO2022047417A1 (en) * | 2020-08-31 | 2022-03-03 | Exuma Biotech Corp. | Anti-idiotype compositions and methods of use thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| PL3443012T3 (pl) * | 2016-04-15 | 2026-04-20 | Bioatla, Inc. | Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| WO2017193059A1 (en) * | 2016-05-06 | 2017-11-09 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| CN116751298A (zh) | 2016-05-13 | 2023-09-15 | 生物蛋白有限公司 | 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途 |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| EP3472318B1 (en) | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| TWI691510B (zh) | 2016-07-12 | 2020-04-21 | 美商凱特製藥公司 | 抗原結合分子和使用彼之方法 |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP7500195B2 (ja) | 2016-08-23 | 2024-06-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
| CN106279438B (zh) * | 2016-08-24 | 2019-10-22 | 北京领柯生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| KR102873209B1 (ko) * | 2016-08-31 | 2025-10-17 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 폴리펩티드 및 이를 제조하는 방법 |
| EP4353319A3 (en) | 2016-09-28 | 2024-06-05 | Atossa Therapeutics, Inc. | Methods of adoptive cell therapy |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| EP3315511A1 (en) * | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018102547A1 (en) * | 2016-12-02 | 2018-06-07 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tag-72-binding chimeric antigen receptors |
| MX2019007981A (es) * | 2017-01-03 | 2019-10-15 | Bioatla Llc | Terapeutica de proteinas para el tratamiento de celulas senescentes. |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
| AU2018226884B2 (en) | 2017-03-03 | 2024-11-07 | Exuma Biotech, Corp. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2018201088A1 (en) * | 2017-04-27 | 2018-11-01 | Washington University | Activation of natural cytotoxicity receptor 2 (ncr2) |
| US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
| EP3638300A4 (en) | 2017-06-16 | 2021-06-23 | Protelica, Inc. | CHIMERIC ANTIGEN RECEPTORS WITH FIBRONECTIN BINDING DOMAIN AND METHOD OF USING THEREOF |
| CN110996974A (zh) | 2017-06-16 | 2020-04-10 | 梅约医学教育与研究基金会 | 增加免疫应答的材料和方法 |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| WO2019008555A1 (en) | 2017-07-07 | 2019-01-10 | Biocon Limited | POLYMORPHIC FORMS OF DASATINIB |
| SG11202000503QA (en) | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| CN109796532B (zh) * | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| CN109957019A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957025A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
| KR20200120917A (ko) * | 2018-02-02 | 2020-10-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 키메라 항원 수용체를 발현하는 변형된 단핵구/대식세포/수지상 세포 및 단백질 응집체와 연관이 있는 질환 및 장애에서의 용도 |
| CN108314739B (zh) * | 2018-02-05 | 2020-07-14 | 深圳市默赛尔生物医学科技发展有限公司 | 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用 |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| KR102795055B1 (ko) | 2018-02-11 | 2025-04-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Car-t 세포 및 자가면역 질환 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| JP7527641B2 (ja) | 2018-04-18 | 2024-08-05 | アブクロン・インコーポレイテッド | スイッチ分子及びスイッチャブルキメラ抗原受容体 |
| EP3784278B1 (en) * | 2018-04-27 | 2025-01-15 | Mayo Foundation for Medical Education and Research | Foamy viruses and methods of use |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112955548B (zh) * | 2018-07-09 | 2023-11-24 | 普众发现医药科技(上海)有限公司 | 叶酸受体α特异性抗体 |
| US20210275589A1 (en) * | 2018-07-13 | 2021-09-09 | Nanjing Legend Biotech Co. Ltd. | Co-receptor systems for treating infectious diseases |
| PT3835415T (pt) * | 2018-08-10 | 2024-12-18 | Univ Kyoto | Método para produção de células positivas para cd3 |
| SG11202100961UA (en) * | 2018-08-21 | 2021-03-30 | Bioatla Inc | CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3847191A4 (en) * | 2018-09-07 | 2022-06-08 | BioAtla, Inc. | CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| US12466892B2 (en) | 2018-11-08 | 2025-11-11 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| US12227551B2 (en) | 2018-12-11 | 2025-02-18 | Obsidian Therapeutics, Inc. | Membrane bound IL12 compositions and methods for tunable regulation |
| CN113271965B (zh) * | 2019-01-11 | 2023-11-03 | 湖南远泰生物技术有限公司 | Cd37抗体和cd37-car-t细胞 |
| CN113795755A (zh) * | 2019-02-14 | 2021-12-14 | 全国儿童医院研究所 | 质膜颗粒、脂质体和外泌体用于测定免疫细胞效力的用途 |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN111825769B (zh) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | 一种泛素化缺失的嵌合抗原受体及其用途 |
| JP7720785B2 (ja) | 2019-04-18 | 2025-08-08 | ブリストル－マイヤーズ スクイブ カンパニー | 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント |
| AU2020257748A1 (en) * | 2019-04-19 | 2021-11-18 | Chugai Seiyaku Kabushiki Kaisha | Chimeric receptor recognizing modification site of antibody |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| JP2022531977A (ja) * | 2019-05-16 | 2022-07-12 | ユニバーシティ オブ ワシントン | 新規に設計された共局在化依存性タンパク質スイッチを使用する超特異的細胞標的化 |
| BR112021024438A2 (pt) * | 2019-06-03 | 2022-02-15 | Univ Chicago | Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno |
| AU2020292304B2 (en) | 2019-06-11 | 2023-03-30 | Bioatla, Inc. | Conditionally active anti-EpCam antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20220281943A1 (en) * | 2019-08-14 | 2022-09-08 | The Regents Of The University Of California | Car-t cells specific for modified proteins in extracellular spaces |
| JP7831937B2 (ja) | 2019-09-03 | 2026-03-17 | クリエイト・メディシンズ，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| TW202134278A (zh) * | 2019-11-08 | 2021-09-16 | 美商胡曼尼根公司 | 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞 |
| CN110964750A (zh) * | 2019-11-13 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| BR112022014568A2 (pt) * | 2020-01-23 | 2022-09-27 | Exuma Biotech Corp | Receptores de antígeno quiméricos contra her2 e métodos de uso dos mesmos |
| CA3167572A1 (en) * | 2020-02-14 | 2021-08-19 | Robbie G. MAJZNER | Chimeric antigen receptors with cd2 activation |
| EP4106802A1 (en) * | 2020-02-17 | 2022-12-28 | Miltenyi Biotec B.V. & Co. KG | Method for providing personalized cells with chimeric antigen receptors (car) against tumor microenvironment cells |
| US12365871B2 (en) * | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN115867294A (zh) | 2020-06-04 | 2023-03-28 | 凯瑞斯马治疗公司 | 嵌合抗原受体的新型构建体 |
| CN112592408B (zh) * | 2020-07-20 | 2021-08-17 | 北京鼎成肽源生物技术有限公司 | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| MX2023005571A (es) * | 2020-11-12 | 2023-07-31 | Bioatla Inc | Metodos de tratamiento de canceres que expresan axl con anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados. |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022203227A1 (ko) * | 2021-03-23 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| CA3226798A1 (en) | 2021-07-29 | 2023-02-02 | James MATTHAEI | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
| EP4405396A2 (en) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| US20250099612A1 (en) | 2022-03-01 | 2025-03-27 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| TW202435912A (zh) | 2022-08-03 | 2024-09-16 | 美商航海家醫療公司 | 用於穿過血腦屏障之組合物及方法 |
| WO2024128219A1 (ja) * | 2022-12-13 | 2024-06-20 | 愛知県 | キメラ抗原受容体 |
| CN116284446A (zh) * | 2023-02-15 | 2023-06-23 | 武汉科技大学 | 一种靶向cd200嵌合型抗原受体及其应用 |
| JP2026507181A (ja) * | 2023-03-02 | 2026-02-27 | バイオアトラ インコーポレイテッド | 条件的活性型抗ＥｐＣＡＭ抗体、抗体断片及びそれを組み込んだ構築物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025198961A1 (en) * | 2024-03-19 | 2025-09-25 | BioAtla, Inc | Methods and pharmaceutical composition for the treatment of adenoid cystic carcinoma |
| WO2026001894A1 (zh) * | 2024-06-24 | 2026-01-02 | 上海医药集团生物治疗技术有限公司 | 靶向axl的嵌合抗原受体及其用途 |
| CN119446257B (zh) * | 2025-01-09 | 2025-05-27 | 苏州系统医学研究所 | 一种基于高通量测序数据的病毒数据处理方法 |
Family Cites Families (246)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683A (en) | 1846-08-08 | waring and richard e | ||
| US195A (en) | 1837-05-15 | Machine fob cutting and dressing stone | ||
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| JPH05236997A (ja) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5427954A (en) | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| KR100332254B1 (ko) | 1993-10-01 | 2002-09-27 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규인펩티드유도체 |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
| US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| SG83659A1 (en) | 1996-01-10 | 2001-10-16 | Kibun Shokuhin Kk | Cylindrical food consisting of plurality of concentric cylindrical layers of food material and method and apparatus for making the same |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| US6300065B1 (en) * | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| CN1273609A (zh) | 1997-08-15 | 2000-11-15 | 希斯克有限公司 | 检测或量化核酸物类的方法和组合物 |
| CN1677076A (zh) | 1997-09-11 | 2005-10-05 | 生物风险公司 | 制备高密度阵列的方法 |
| US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| AU3463699A (en) | 1998-04-03 | 1999-10-25 | Phylos, Inc. | Addressable protein arrays |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
| DE69930328T2 (de) | 1998-08-27 | 2006-12-14 | Spirogen Ltd., Ryde | Dimere Pyrrolobenzodiazepine |
| US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
| US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20090130718A1 (en) | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
| US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| EP1106603A3 (en) | 1999-12-06 | 2003-11-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
| ATE344801T1 (de) | 1999-12-29 | 2006-11-15 | Immunogen Inc | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| JP3924113B2 (ja) | 2000-05-15 | 2007-06-06 | 株式会社日立グローバルストレージテクノロジーズ | 複数のヘッドサスペンションアッセンブリを有するヘッドキャリッジアッセンブリ及びこれを用いた磁気ディスク装置 |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| JP4148883B2 (ja) | 2002-12-18 | 2008-09-10 | 株式会社パイオラックス | グローブボックス用リッドロック装置 |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| DE60326060D1 (de) | 2003-03-31 | 2009-03-19 | Council Scient Ind Res | Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
| US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| EP1791569A4 (en) * | 2004-08-23 | 2009-12-16 | Univ Emory | Improved selection of-ph dependent compounds for in vivo therapy |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US20100255004A1 (en) | 2007-04-13 | 2010-10-07 | Dana Farber Cancer Institute | Receptor tyrosine kinase profiling |
| PL2019104T3 (pl) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
| US7947495B2 (en) | 2007-11-01 | 2011-05-24 | Abbott Biotherapeutics Corp. | Immunoglobulin display vectors |
| AU2008323206B2 (en) | 2007-11-12 | 2014-08-14 | U3 Pharma Gmbh | AXL antibodies |
| CA2706549A1 (en) | 2007-11-15 | 2009-05-22 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| US8742076B2 (en) | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| CN102159248B (zh) | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US9464284B2 (en) | 2009-03-09 | 2016-10-11 | Bioatla, Llc | Mirac proteins |
| ES2543095T3 (es) * | 2009-07-10 | 2015-08-14 | Innate Pharma | Agentes de unión a TLR3 |
| ES2652340T3 (es) | 2009-07-17 | 2018-02-01 | Bioatla Llc | Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción |
| FR2948364B1 (fr) | 2009-07-21 | 2011-07-15 | Rhodia Operations | Procede de preparation d'un fluorure d'halogenoacetyle et de ses derives |
| WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| TWI518325B (zh) * | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
| WO2011109726A2 (en) | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| FI20105715A0 (fi) | 2010-06-18 | 2010-06-18 | Helsingin Yliopisto | Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine |
| CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| ES2754394T3 (es) * | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| WO2012044831A1 (en) | 2010-09-30 | 2012-04-05 | Board Of Trustees Of Northern Illinois University | Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents |
| AR084020A1 (es) | 2010-11-30 | 2013-04-17 | Genentech Inc | Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
| US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| GB201108236D0 (en) * | 2011-05-17 | 2011-06-29 | Ucl Business Plc | Method |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| RU2732151C2 (ru) * | 2011-09-30 | 2020-09-11 | Чугаи Сейяку Кабусики Кайся | Библиотека зависимых от концентрации ионов связывающих молекул |
| US20140322234A1 (en) | 2012-01-03 | 2014-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis and Targeting of ROR2 in Cancer |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| MX2014010185A (es) | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| CA3205751A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| KR101721678B1 (ko) * | 2012-03-08 | 2017-03-31 | 할로자임, 아이엔씨 | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 |
| US9511152B2 (en) * | 2012-04-05 | 2016-12-06 | The Board Of Regents Of The University Of Texas System | Multicolored pH-activatable fluorescence nanoplatform |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| DK2847231T3 (da) | 2012-05-10 | 2019-10-14 | Bioatla Llc | Multispecifikke monoklonale antistoffer |
| US20160235787A1 (en) * | 2012-07-13 | 2016-08-18 | The Trustees Of The University Of Pennsylvania | Epitope Spreading Associated with CAR T-Cells |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| EP4303232A3 (en) * | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| CN105940102B (zh) * | 2013-08-26 | 2020-02-18 | 海瑞克·亚柏坎 | 抗cd30嵌合抗原受体及其用途 |
| MX2016003256A (es) | 2013-09-12 | 2016-06-07 | Halozyme Inc | Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos. |
| GB201402631D0 (en) | 2014-02-14 | 2014-04-02 | Alligator Bioscience Ab | Library |
| WO2016033331A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016036916A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| AU2016222830B2 (en) | 2015-02-24 | 2021-02-25 | Bioatla Llc | Conditionally active biological proteins |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
-
2015
- 2015-08-27 WO PCT/US2015/047197 patent/WO2016033331A1/en not_active Ceased
- 2015-08-27 RU RU2017109966A patent/RU2764074C2/ru active
- 2015-08-27 KR KR1020237043017A patent/KR102818922B1/ko active Active
- 2015-08-27 ES ES15836397T patent/ES2913865T3/es active Active
- 2015-08-27 DK DK22164162.4T patent/DK4074735T3/da active
- 2015-08-27 MX MX2017002605A patent/MX2017002605A/es unknown
- 2015-08-27 EP EP15836397.8A patent/EP3186284B1/en active Active
- 2015-08-27 CN CN201580057728.0A patent/CN107074975A/zh active Pending
- 2015-08-27 JP JP2017511696A patent/JP7286267B2/ja active Active
- 2015-08-27 ES ES22164162T patent/ES3034398T3/es active Active
- 2015-08-27 EP EP22164162.4A patent/EP4074735B1/en active Active
- 2015-08-27 US US15/504,470 patent/US20170260261A1/en not_active Abandoned
- 2015-08-27 AU AU2015308818A patent/AU2015308818B2/en active Active
- 2015-08-27 KR KR1020177006675A patent/KR102615681B1/ko active Active
- 2015-08-27 DK DK15836397.8T patent/DK3186284T3/da active
-
2016
- 2016-02-24 KR KR1020247007173A patent/KR102889461B1/ko active Active
- 2016-02-24 JP JP2018530483A patent/JP7048494B2/ja active Active
- 2016-02-24 EP EP16839728.9A patent/EP3341406A4/en active Pending
- 2016-02-24 WO PCT/US2016/019255 patent/WO2017034615A1/en not_active Ceased
- 2016-02-24 MX MX2018002400A patent/MX2018002400A/es unknown
- 2016-02-24 HK HK18106062.0A patent/HK1246803A1/zh unknown
- 2016-02-24 RU RU2018110553A patent/RU2759957C2/ru active
- 2016-02-24 BR BR112018003535A patent/BR112018003535A2/pt not_active Application Discontinuation
- 2016-02-24 CN CN201680049877.7A patent/CN107922473A/zh active Pending
- 2016-02-24 AU AU2016313107A patent/AU2016313107A1/en not_active Abandoned
- 2016-02-24 US US15/052,487 patent/US20160207989A1/en not_active Abandoned
- 2016-02-24 CA CA2996514A patent/CA2996514A1/en active Pending
- 2016-02-24 KR KR1020187006771A patent/KR102646445B1/ko active Active
- 2016-02-24 US US15/753,872 patent/US20190010219A1/en not_active Abandoned
-
2017
- 2017-02-27 MX MX2022007894A patent/MX2022007894A/es unknown
-
2018
- 2018-02-26 MX MX2022009625A patent/MX2022009625A/es unknown
- 2018-08-02 US US16/053,166 patent/US11584927B2/en active Active
-
2021
- 2021-05-14 JP JP2021082062A patent/JP7405444B2/ja active Active
- 2021-06-16 AU AU2021203997A patent/AU2021203997B2/en active Active
-
2022
- 2022-12-02 US US18/061,197 patent/US20230183679A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532014A5 (https=) | ||
| RU2017109966A (ru) | Условно активные химерные антигенные рецепторы для модифицированных т-клеток | |
| Zhang et al. | Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy | |
| JP2018529376A5 (https=) | ||
| JP7382829B2 (ja) | キメラ抗原受容体を発現するｔ細胞 | |
| AU2010343057B2 (en) | Heterodimer binding proteins and uses thereof | |
| EP4527466A2 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| US20210177951A1 (en) | Engineered cells & methods | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| JP2016514462A5 (https=) | ||
| CN104203981A (zh) | 双特异性抗体分子 | |
| JP2015527070A5 (https=) | ||
| JP7254710B2 (ja) | Ｃｄ３７を標的にするキメラ抗原受容体 | |
| CA3063169A1 (en) | T cells expressing a chimeric antigen receptor | |
| JP2021530971A (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| Yao et al. | The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances | |
| JP2024527408A (ja) | 記憶ナチュラルキラー細胞の拡大 | |
| CN112442509A (zh) | Cd19-cd20双特异性和双通道car-t及其使用方法 | |
| WO2023202280A1 (zh) | 抗B7H6的scFv抗体、其编码基因及其应用 | |
| Kim et al. | Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors | |
| WO2021022044A1 (en) | Depletion regimes for engineered t-cell or nk-cell therapy | |
| Kamat et al. | CAR-T Cells: Design Principles, Core Concepts, and Clinical Applications | |
| KR20260042160A (ko) | 이중특이적 폴리펩티드 분자 | |
| Strohl et al. | Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill | |
| WO2025251008A1 (en) | Cd19 antibodies and methods of using same |